149 related articles for article (PubMed ID: 34278503)
1. Tumorigenic effect of
Yang L; Li N; Wang M; Zhang YH; Yan LD; Zhou W; Yu ZQ; Peng XC; Cai J
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34278503
[TBL] [Abstract][Full Text] [Related]
2. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
3. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer.
Mavrogiannou E; Strati A; Stathopoulou A; Tsaroucha EG; Kaklamanis L; Lianidou ES
Clin Chem; 2007 Jan; 53(1):53-61. PubMed ID: 17130181
[TBL] [Abstract][Full Text] [Related]
4. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
[TBL] [Abstract][Full Text] [Related]
5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
6. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
8. Concordant expression of the telomerase-associated genes in non-small cell lung cancer.
Hsu CP; Miaw J; Hsia JY; Shai SE; Chen CY
Eur J Surg Oncol; 2003 Sep; 29(7):594-9. PubMed ID: 12943625
[TBL] [Abstract][Full Text] [Related]
9. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
11. Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.
McKelvey BA; Umbricht CB; Zeiger MA
Front Endocrinol (Lausanne); 2020; 11():485. PubMed ID: 32849278
[No Abstract] [Full Text] [Related]
12. Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression.
Zhang B; Ling T; Zhaxi P; Cao Y; Qian L; Zhao D; Kang W; Zhang W; Wang L; Xu G; Zou X
Cancer Lett; 2019 Jun; 452():23-30. PubMed ID: 30910586
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
14. Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.
McKelvey BA; Zeiger MA; Umbricht CB
Mol Oncol; 2020 Oct; 14(10):2355-2357. PubMed ID: 32920953
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells.
Deng WG; Jayachandran G; Wu G; Xu K; Roth JA; Ji L
J Biol Chem; 2007 Sep; 282(36):26460-70. PubMed ID: 17630431
[TBL] [Abstract][Full Text] [Related]
16. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
17. Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer.
Wu XQ; Huang C; He X; Tian YY; Zhou DX; He Y; Liu XH; Li J
Cell Signal; 2013 Dec; 25(12):2462-8. PubMed ID: 23993966
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.
Serrano D; Bleau AM; Fernandez-Garcia I; Fernandez-Marcelo T; Iniesta P; Ortiz-de-Solorzano C; Calvo A
Mol Cancer; 2011 Aug; 10():96. PubMed ID: 21827695
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
[TBL] [Abstract][Full Text] [Related]
20. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
